Hepatitis C virus (HCV) is an emerging public health problem with over 180 million people infected worldwide. 1 In the United States (US), approximately 3.2 million people are affected. 2 Human immunodefi ciency virus (HIV) is also one of the biggest health concerns globally, with 33 million people infected worldwide 3 and 1.2 million people infected in the US. 4 Over time, chronically infected patients develop complications such as cirrhosis of the liver and hepatocellular carcinoma. The CDC estimates nearly 8,000-10,000 deaths due to chronic liver disease each year. Co-infection with HCV and HIV can result in more rapid disease progression and a higher prevalence of cirrhosis 5 leading to increased disease burden.
OBJECTIVES
To generate national estimates of per-discharge inpatient costs, length of stay (LOS), and probability of death among patients infected with chronic HCV, HIV, and those co-infected with both. Results were compared with patients without chronic HCV or HIV.
METHODS

Study Design
Retrospective database analysis
Data Source
Discharge data were collected from the 2005 Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample (NIS). 6 • The NIS is the largest all-payer inpatient care database in the US.
• The 2005 NIS dataset contains data for approximately 8 million inpatient stays.
• The NIS is the only national hospital database with charge information on all patients, regardless of payer, including those covered by Medicare, Medicaid, private insurance, and the uninsured).
• The NIS includes numerous demographic, clinical, and resource use variables for each inpatient stay, including patient age, gender, and race, diagnosis codes, LOS, total charges, admission and discharge status, payer, and hospital-specifi c characteristics.
• Sampling weights allow for generating nationally representative estimates.
• Steiner and colleagues (2002) provide a comprehensive review of this source and other HCUP data sources. 7
Inclusion Criteria
Criteria for inclusion in the study were as follows:
• 
Statistical Techniques
• All analyses were conducted using SUDAAN ® software, version 9.0, to account for the NIS's complex survey design.
• T-tests were used to test for signifi cant differences in outcomes between groups. 
CONTACT INFORMATION
RESULTS
Patient Characteristics (Table 1) • There were 39,163,834 discharges in the US in 2005.
• Among these:
-390,966 were for chronic-HCV only -136,596 were for HIV only -26,000 were for chronic HCV and HIV co-infection -38,610,272 were unrelated to chronic HCV or HIV.
• Patients with chronic HCV only were slightly older on average (51 years) compared to those with HIV only (43 years) and HCV and HIV co-infection (46 years).
• A greater proportion of patients in the three study groups were male (61% to 70%) compared to the group without HCV or HIV (42%).
• Patients hospitalized for HCV or HCV and HIV co-infection were predominantly black.
• Medicare and Medicaid were the primary payers for over half of the discharges in the study sample. The proportion of patients receiving Medicaid in the three study groups of interest was greater than that of the comparator group.
Hospital Characteristics (Table 2) • Patients with HCV and HIV co-infection were more likely to be seen in an urban hospital.
• Most hospitals were located in the South (37% to 48%).
• The distribution of hospital bed size was similar across the three study groups and the comparator group.
• Over 60% of all HIV-related discharges were at teaching hospitals. (Figures 1a and 1b) • Total cost per hospitalization was lowest for HCV at $11,795 and was signifi cantly higher for HIV ($14,594) and for HCV and HiV co-infection ($14,686). The total hospitalization cost for the comparator group was nearly half ($8,859), P < 0.01 for all three groups.
Costs Associated With Chronic HCV-Related Complications
• Cost per day, however, was lower for all three groups compared to those without HCV or HIV, although the difference was not statistically signifi cant for those with chronic HCV only.
Length of Stay and Probability of Death (Figures 2a and 2b)
• The average LOS for chronic HCV-related hospitalizations was 6.03 days, while that for HIV-related hospitalizations and for HCV and HIV co-infection was higher at 7.87 days. In comparison, hospitalizations not related to HCV or HIV had an average LOS of only 4.62 days, P < 0.01 for all three groups.
• The probability of death associated with HCV only, HIV only, and HCV and HIV co-infection was 3.5%, 5.1%, and 5.6%, respectively. The probability of death associated with non-HCV or HIV-related hospitalizations combined was only 2.1%, P < 0.01 for all three groups.
LIMITATION
• Conditions were identifi ed based on diagnosis codes, which if recorded inaccurately, may cause some discharges to be misidentifi ed as chronic HCV-or HIV-related.
CONCLUSIONS
• This is one of few studies to quantify differences in inpatient costs and outcomes associated with HCV, HIV, and HCV and HIV co-infection in a multipayer US population.
• Hospitalizations related to HCV and HIV co-infection were longer and more expensive compared to those related to HCV only.
• Policy makers and other decision makers should be aware of this burden as strategies to allocate resources are developed. 
